Key facts
- This page summarizes Sumita Ray's Form 3 filing for Cue Biopharma, Inc. (CUE).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Jun 2026, 17:47.
Sumita Ray - 01 Jun 2026 Form 3 Insider Report for Cue Biopharma, Inc. (CUE)
- Reporting relationship
- Chief Legal Compliance Officer, Corporate Secretary
- Issuer ticker
- CUE
- Reported as of
- 01 Jun 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 11 Jun 2026, 17:47:31 UTC
- Prior SEC filing
- 13 Jun 2025
- Next SEC filing
- 12 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sumita Ray
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sumita Ray filed Form 3 for Cue Biopharma, Inc. (CUE) on 11 Jun 2026.
Change
- Previous filing in this sequence was filed on 13 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001579629
Primary reporting owner
Ray Sumita
- Relationship
- Chief Legal Compliance Officer, Corporate Secretary
- Address
- C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
- Signature
- /s/ Sumita Ray
- Signature date
- 11 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CUE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 54,589
- Date
- 01 Jun 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CUE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 109,179
- Exercise price
- $30.42
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option becomes exercisable in equal, quarterly installments over four years measured from May 1, 2026.